Day 1 - 10 May 2017
Meeting category
Date(s)
10 May 2017 - 11 May 2017
Location
Málaga,
Spain
Organizer
Spanish HIV Clinical Forum 2017
Related Enduring Materials
Enduring Materials
Session 1: State of the ART: Current Clinical Management -
2016-2017 - Key Advances in HIV Treatment
Update on HIV Transmitted and Acquired Integrase Resistance in Spain - Relevance to Routine Clinical Practice
Abstract presentations
Prevalence of Transmitted Drug Resistance Mutations among Naïve HIV-infected patients (2014-2016) in Northwest Spain
B. Pernas Souto, Instituto De Investigación Biomédica De A Coruña (inibic)-complexo Hospitalario Universitario De A Coruña (CHUAC), Spain
Primary Resistance to Integrase Strand-Transfer Inhibitors in Spain, 2015-2016
M. Casadellà, IrsiCaixa AIDS Research Institute, Spain
Transmisión de mutaciones de resistencias a inhibidores de la integrasa
I. Viciana, UGC de Enfermedades Infecciosas y Microbiología Clínica,Hospital Virgen de la Victoria, Spain
Mutaciones a Inhibidores de la Integrasa en la vida real
I. Viciana, UGC de Enfermedades Infecciosas y Microbiología Clínica,Hospital Virgen de la Victoria, Spain
Session 2: Reducing Drug Regimens: What is the Magic Number? -
Reduced drug regimens, what’s the magic number: three, two or one? – Overview
Virological perspective
Pharmacological perspective
Toxicity and co-morbidities perspective
Clinical case on reduced drug regimen with integrase inhibitors
Day 2 - 11 May 2020
Session 3: Prevention -
HIV Prevention 2.0
PrEP and prevention
Abstract presentations
Eficacia y seguridad de dolutegravir más rilpivirina en la vida real. Resultados a 24 semanas. Estudio DORIVIR
J. Santos, Hospital Virgen de la Victoria, Spain
Dolutegravir and lamivudine as dual maintenance therapy
R. Montejano, Hospital Universitario La Paz, Madrid, Spain
Reasons for discontinuation of dual therapy with dolutegravir and riplivirine
R. Montejano, Hospital Universitario La Paz, Madrid, Spain
Dolutegravir (DTG) based antiretroviral therapy (ART) discontinuation in clinical practice
V. Moreno-Torres, Hospital Puerta De Hierro Majadahonda, Spain
Experiencia con Inhibidores de la Integrasa en un hospital terciario
I. Mur, Hospital De La Santa Creu I Sant Pau, Spain
Overview
Welcome
The 2nd Spanish HIV Clinical Forum was held on 10-11 May 2017 in Málaga (Spain), preceding the SEIMC 2017.
The meeting was a success with great lectures and exciting discussions! Thank you to our conference supporter Laboratorios ViiV Healthcare for making this meeting possible and to our endorsers: AIDS Action Europe, GeSIDA, HealthHIV, IAPAC, SAEI, and SEIMC for supporting this meeting!
The Spanish HIV Clinical Forum focused entirely on the Spanish community and Integrase Inhibitors as Integrase Inhibitors are rapidly gaining a central role in the routine care of HIV infected individuals. The HIV Clinical Forum meetings aim at enhancing the clinical skills and research capabilities of HIV healthcare professionals in regard to this unique class of antiretroviral drugs.
Background
The HIV CLINICAL FORUM is developed as part of a series of interactive programs that provide independent medical education on emerging topics in HIV. The program features International and regions experts in order to provide HIV clinicians and allied healthcare professionals with updates on the latest developments related to HIV management, providing opportunities for sharing of clinical experience and presenting results from ongoing and completed cohorts/research programs.
Support
Support
Endorsers
Endorsers
